CN100425231C - 丹红口服制剂及其制备方法 - Google Patents
丹红口服制剂及其制备方法 Download PDFInfo
- Publication number
- CN100425231C CN100425231C CNB2006101286478A CN200610128647A CN100425231C CN 100425231 C CN100425231 C CN 100425231C CN B2006101286478 A CNB2006101286478 A CN B2006101286478A CN 200610128647 A CN200610128647 A CN 200610128647A CN 100425231 C CN100425231 C CN 100425231C
- Authority
- CN
- China
- Prior art keywords
- danshensu
- preparation
- oral formulation
- tablet
- safflower yellow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 title claims description 63
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 title claims description 63
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 title claims description 63
- 238000002360 preparation method Methods 0.000 title claims description 46
- 239000000203 mixture Substances 0.000 title claims description 35
- 238000009472 formulation Methods 0.000 title claims description 25
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 title claims description 23
- 239000003814 drug Substances 0.000 claims abstract description 18
- 239000002775 capsule Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 59
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 claims description 33
- 241000208809 Carthamus Species 0.000 claims description 33
- 241000628997 Flos Species 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 13
- 230000001476 alcoholic effect Effects 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 8
- 239000013078 crystal Substances 0.000 claims description 8
- 238000004821 distillation Methods 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 238000001179 sorption measurement Methods 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 229940023488 pill Drugs 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- QWVMSYBGKWZIIE-RDFNRINOSA-N Flavochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CCCC(C)(C)C2=C1)C=CC=C(/C)C=CC3C(=CCCC3(C)C)C QWVMSYBGKWZIIE-RDFNRINOSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- QWVMSYBGKWZIIE-FZKBJVJCSA-N flavochrome Chemical compound O1C2(C)CCCC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1C(C)=CCCC1(C)C QWVMSYBGKWZIIE-FZKBJVJCSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 235000008504 concentrate Nutrition 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000013270 controlled release Methods 0.000 claims description 4
- 239000007919 dispersible tablet Substances 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 230000005484 gravity Effects 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000001117 sulphuric acid Substances 0.000 claims description 3
- 235000011149 sulphuric acid Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000006190 sub-lingual tablet Substances 0.000 claims description 2
- 229940098466 sublingual tablet Drugs 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 10
- 239000008522 danhong Substances 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 5
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 5
- 208000029078 coronary artery disease Diseases 0.000 abstract description 5
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 abstract 2
- 244000132619 red sage Species 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 108010011485 Aspartame Proteins 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000000605 aspartame Substances 0.000 description 7
- 235000010357 aspartame Nutrition 0.000 description 7
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 7
- 229960003438 aspartame Drugs 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000010936 aqueous wash Methods 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 235000011121 sodium hydroxide Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001054 red pigment Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical class COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006101286478A CN100425231C (zh) | 2006-09-04 | 2006-09-04 | 丹红口服制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006101286478A CN100425231C (zh) | 2006-09-04 | 2006-09-04 | 丹红口服制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1965821A CN1965821A (zh) | 2007-05-23 |
CN100425231C true CN100425231C (zh) | 2008-10-15 |
Family
ID=38074914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006101286478A Active CN100425231C (zh) | 2006-09-04 | 2006-09-04 | 丹红口服制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100425231C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102357118A (zh) * | 2011-11-03 | 2012-02-22 | 哈药集团中药二厂 | 丹参提取物和红花提取物的提取方法及丹红口服制剂的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1520859A (zh) * | 2003-01-28 | 2004-08-18 | 黄衍民 | 治疗心脑血管病的丹红注射液 |
CN1686389A (zh) * | 2005-04-11 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | 一种以丹参、红花制备而成的丹红滴丸及其制备方法 |
CN1704113A (zh) * | 2004-02-20 | 2005-12-07 | 于文勇 | 治疗心脑血管疾病的中药丹红制剂及其制备方法 |
CN1778348A (zh) * | 2004-11-23 | 2006-05-31 | 郭爱华 | 一种治疗心脑血管注射用丹红冻干粉针剂及制备方法 |
-
2006
- 2006-09-04 CN CNB2006101286478A patent/CN100425231C/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1520859A (zh) * | 2003-01-28 | 2004-08-18 | 黄衍民 | 治疗心脑血管病的丹红注射液 |
CN1704113A (zh) * | 2004-02-20 | 2005-12-07 | 于文勇 | 治疗心脑血管疾病的中药丹红制剂及其制备方法 |
CN1778348A (zh) * | 2004-11-23 | 2006-05-31 | 郭爱华 | 一种治疗心脑血管注射用丹红冻干粉针剂及制备方法 |
CN1686389A (zh) * | 2005-04-11 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | 一种以丹参、红花制备而成的丹红滴丸及其制备方法 |
Non-Patent Citations (2)
Title |
---|
红花黄色素冻干粉针剂与红花黄色素滴注也治疗冠心病绞痛的临床非劣性试验. 张琼.中国循证医学杂志,第5卷第4期. 2005 |
红花黄色素冻干粉针剂与红花黄色素滴注也治疗冠心病绞痛的临床非劣性试验. 张琼.中国循证医学杂志,第5卷第4期. 2005 * |
Also Published As
Publication number | Publication date |
---|---|
CN1965821A (zh) | 2007-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102423352B (zh) | 一种治疗心脑血管疾病的中药颗粒剂的制备方法 | |
CN101766694A (zh) | 肉苁蓉总苷提取工艺及其制剂 | |
CN103340841A (zh) | 一种中药膜剂、其制备方法和用途 | |
CN102068579B (zh) | 一种治疗气滞型胃脘痛、促进胃肠蠕动、治疗便秘的中药 | |
CN1887324B (zh) | 一种治疗肝肾不足的中药组合物及其制备方法和分析方法 | |
CN101874841A (zh) | 巴戟天属植物总苷提取物及其制备方法和用途 | |
CN101926869B (zh) | 一种治疗头晕、头痛的药物及其制备方法 | |
CN100425231C (zh) | 丹红口服制剂及其制备方法 | |
CN100509009C (zh) | 一种治疗心脑血管病、缺血性中风的中药制剂及其制备方法 | |
CN101850065B (zh) | 一种治疗痛风的中药组合物 | |
CN1413697A (zh) | 中药六味地黄制剂的生产方法 | |
CN100584358C (zh) | 一种治疗心脑血管病的中药组合物及其制剂和制备方法 | |
CN103479763B (zh) | 一种治疗临界高血压的中药组合物及其制备方法 | |
CN101269123A (zh) | 消渴降糖胶囊二次开发的新工艺 | |
US7179492B2 (en) | Traditional chinese pharmaceutical formulation for treatment of paradentosis, process for preparation and use thereof | |
CN101766683B (zh) | 一种丹参分散片及其应用 | |
CN101239145A (zh) | 栝蒌薤白半夏口服制剂及其制备方法 | |
CN101190282B (zh) | 一种治疗上呼吸道感染的无糖复方中药制剂及其质量控制方法 | |
CN109078072A (zh) | 一种用于预防冠心病的口服制剂 | |
CN1456230A (zh) | 六味地黄片的制备方法 | |
CN100435842C (zh) | 治疗高血压病的中药制剂及制备方法 | |
CN102008587A (zh) | 治疗肝癌中药制剂及其制备方法 | |
CN101974012A (zh) | 一种具有药用活性的新化合物灯盏细辛酸乙酯 | |
CN100512800C (zh) | 一种治疗脑中风疾病的口腔崩解片及其制备方法 | |
CN101856357A (zh) | 救必应酸在制备防治心脑血管疾病的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BIOCHEMICAL PHARMACEUTICAL FACTORY, ZHUHAI SPECIAL Free format text: FORMER OWNER: GUO AIHUA Effective date: 20130312 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 519015 ZHUHAI, GUANGDONG PROVINCE TO: 519041 ZHUHAI, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130312 Address after: 519041 Guangdong province Zhuhai Sanzao Jinhai Road No. 6 Patentee after: Biochemical Pharmaceutical Factory of Zhuhai S.E.Z. Address before: 519015 Guangdong province Zhuhai Jida Garden Road No. 1 building 13 7A Patentee before: Guo Aihua |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 519041 Guangdong province Zhuhai Sanzao Jinhai Road No. 6 Patentee after: Zhuhai homologous Pharmaceutical Co., Ltd. Address before: 519041 Guangdong province Zhuhai Sanzao Jinhai Road No. 6 Patentee before: Biochemical Pharmaceutical Factory of Zhuhai S.E.Z. |